CN1342160A - 8-氰基-1-环丙基-7-(1s,6s-2,8-二氮杂双环[4.3.0]壬-8-基)-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸的结晶变体c - Google Patents
8-氰基-1-环丙基-7-(1s,6s-2,8-二氮杂双环[4.3.0]壬-8-基)-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸的结晶变体c Download PDFInfo
- Publication number
- CN1342160A CN1342160A CN00804355A CN00804355A CN1342160A CN 1342160 A CN1342160 A CN 1342160A CN 00804355 A CN00804355 A CN 00804355A CN 00804355 A CN00804355 A CN 00804355A CN 1342160 A CN1342160 A CN 1342160A
- Authority
- CN
- China
- Prior art keywords
- ccdc
- variant
- diazabicyclo
- cyclopropyl
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明涉及一种界定的式(I)的8-氰基-1-环丙基-7-(1S,6S-2,8-二氮杂双环[4.3.0]壬-8-基)-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸的结晶变体,涉及其制备方法并涉及其在药物制剂方面的应用。该结晶变体与式(I)的8-氰基-1-环丙基-7-(1S,6S-2,8-二氮杂双环[4.3.0]壬-8-基)-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸的其它结晶变体的区别在于其特征X射线粉末衍射图及其差热分析图。
Description
本发明涉及一种界定的8-氰基-1-环丙基-7-(1S,6S-2,8-二氮杂双环[4.3.0]壬-8-基)-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸的结晶变体,涉及其制备方法并涉及其在药物制备方面的应用。
CCDC由DE-A 19 633 805或PCT申请97 903 260.4可知。根据这些出版物,它是通过使7-氯-8-氰基-1-环丙基-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸与(1S,6S)-2,8-二氮杂双环[4.3.0]壬烷在二甲基甲酰胺和乙腈的混合物中于辅助碱存在下反应而制备的。将水加入到混合物中,然后用二氯甲烷从水中提取出CCDC并通过除去萃取剂进行分离。这样得到结晶变体不明显的粉末。相反,粉末主要是无定形的并可包含不同结晶变体的混合物。如果偶然形成了一种均匀的结晶变体,则尚不清楚如何提取并确切地得到它。但是,制备药物的先决条件是,对于一种可以不同结晶变体存在的活性化合物,可以明确指出其哪一个结晶变体可用于制备药物。
而且由上述制备方法获得的部分无定形粉末是易吸湿的。但是,无定形固体,并且特别是易吸湿固体,在进行药物加工时难以处理,因为例如它们具有低的本体密度和不能令人满意的流动性能。而且,处理易吸湿固体需要特殊工艺和设备以获得可重复性结果,例如活性化合物含量或所产生固体制剂的稳定性。
因此,本发明的目的是制备所界定的CCDC变体的结晶形式,由于其物理性能,特别是其结晶性能,而易于在药物制剂中进行处理。
根据本发明,该目的是通过一种CCDC的新型结晶形式实现的,该形式在下文中被称作变体C。
因此,本发明提供了CCDC的结晶变体C,其特征在于其具有带有列于下表1中的高和中等强度(>15%相对强度)反射信号(2θ)的X射线粉末衍射图。
表1:
CCDC的变体C的X射线粉末衍射图
2θ(2theta)
5.7
12.6
15.5
17.2
20.2
26.4
27
变体C的特征X射线粉末衍射图还示于图1中。
而且,根据本发明的CCDC变体C在许多其它性能方面也不同于其它形式的CCDC。这些性能本身或与其它参数一起还可用于表征根据本发明的CCDC变体C。
CCDC变体C以通过差热分析(DTA)测定的235-237℃的熔点为特征。特征差热图谱示于图2中。
CCDC变体C的特征在于其具有如图3所示的在KBr中测定的红外图谱。
CCDC变体C的进一步特征是它可通过下面给出的制备方法得到。将未知变体CCDC或无定形CCDC在室温下在至少92%的相对大气湿度下储存数天直到重量不再增加为止,干燥所得的含水的产物,然后加热到高于重排温度的温度,得到CCDC的结晶变体C。
含水产物可通过常规方法干燥。因此例如可在减压下于高温干燥含水产物。也可以在常规干燥剂如五氧化二磷存在下进行干燥。
将干燥样品转化成变体C所需的温度可由干燥物质的DTA确定。一般为150-180℃。
CCDC的结晶变体C令人惊讶地稳定,即使长期储存也不变成另一种结晶变体或无定形形式。由于这些原因,其高度适于制备片剂或其它固体制剂。由于其稳定性,它赋予这些制剂所需的长期储存稳定性。因此使用结晶变体C可以以界定的和目标的方式制备稳定的CCDC固体制剂。
CCDC的结晶变体C在人类或兽医药品领域对病原菌是高度活性的。其广泛的使用范围对应于相应的CCDC。
表征CCDC结晶变体C的X射线粉末衍射图是使用来自Stoe公司的带有位置敏感探测仪(PSD2)的传动衍射仪STADI-P获得的。
差热分析的熔点是使用来自Mettler-Toledo公司的DSC 820装置获得的。在此CCDC结晶变体C样品在铝坩埚中暴露于大气中以10K/min被加热。
IR光谱是使用来自Perkin-Elmer的881装置在KBr中获得的。
下列实施例非限制性地说明了本发明。下面实施例中所用稀释剂/碱体系是特别优选的。对比例
将3.07g 7-氯-8-氰基-1-环丙基-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸、1.39g(1S,6S)-2,8-二氮杂双环[4.3.0]壬烷、2.24g 1,4-二氮杂双环[2.2.2]辛烷(DABCO)、29.5ml二甲基甲酰胺和29.5ml乙腈的混合物在室温搅拌16小时。使用旋转蒸发器在60℃的水浴下将反应混合物浓缩,并将残余物吸收在10ml水中。使用稀盐酸将所得溶液pH调节为7并过滤掉固体。每次使用20ml二氯甲烷将滤液提取3次。有机相经硫酸钠干燥、过滤并使用旋转蒸发器在60℃的浴温下将滤液浓缩。得到2.4g浅棕色固体,其X射线粉末衍射图示于图4中,主要是无定形的。
实施例1
先将1012g 7-氯-8-氰基-1-环丙基-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸加入到3300ml乙醇、1980ml N-甲基吡咯烷酮和534g Hünig碱的混合物中。将该混合物加热回流,并随后滴加459g(1S,6S)-2,8-二氮杂双环[4.3.0]壬烷。滴加完毕后,将混合物在回流下再搅拌3小时,然后冷却至室温,抽滤过滤掉固体并用总共1800ml乙醇洗涤。
将所得固体悬浮在4650ml乙醇和41g Hünig碱的混合物中,并将该反应混合物加热回流3小时。再次将反应混合物冷却至室温,并抽滤过滤掉目体,用总共1000ml EtOH洗涤并在真空干燥箱中于60-70℃干燥直至恒重。得到1130g浅褐色固体,其X射线粉末衍射图示于图5中。
将500mg按照该步骤制备的固体在室温下在95%的相对大气湿度下(用具有沉淀的Na2HPO4×12H2O的饱和水溶液建立)储存11天。由此得到695mg产物。
将200mg所得固体在100℃在真空干燥箱中用P2O5干燥24小时。得到了134mg固体,根据X射线粉末衍射图(图6),该固体基本上是无定形的并具有图7所示的DTA。
将30mg如此获得的固体在180℃于氮气氛下加热2小时。得到27mg固体,其X射线粉末衍射图示于图1,差热分析图示于图2,而IR光谱图示于图3中。
Claims (7)
1. 8-氰基-1-环丙基-7-(1S,6S-2,8-二氮杂双环[4.3.0]壬-8-基)-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸(CCDC)结晶变体C,其特征在于其具有带有下列高和中等强度反射信号(2θ)的X射线粉末衍射图:
2θ(2theta)
5.7
12.6
15.5
17.2
20.2
26.4
27
2. 8-氰基-1-环丙基-7-(1S,6S-2,8-二氮杂双环[4.3.0]壬-8-基)-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸(CCDC)结晶变体C,其特征在于其具有带有下列高和中等强度反射信号(2θ)的X射线粉末衍射图和由DTA测定的235-237℃的熔点:
2θ(2theta)
5.7
12.6
15.5
17.2
20.2
26.4
27
3. 8-氰基-1-环丙基-7-(1S,6S-2,8-二氮杂双环[4.3.0]壬-8-基)-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸(CCDC)结晶变体C,它可通过下述方法获得:将未知变体CCDC或无定形CCDC暴露在至少92%的相对大气湿度下直到重量不再增加为止,然后干燥所得的产物,并随后加热到高于重排温度的温度。
4.制备CCDC变体C的方法,其特征在于,将未知变体CCDC或无定形CCDC暴露在至少92%的相对大气湿度下直到重量不再增加为止,然后干燥所得的产物,并随后加热到高于重排温度的温度。
5.药物,其特征在于,除了常规助剂和赋形剂外,它还包含根据权利要求1-3任一项的CCDC变体C。
6.权利要求1-3任一项的CCDC变体C在制备药物方面的应用。
7.权利要求1-3任一项的CCDC变体C在抗菌组合物中的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19908449A DE19908449A1 (de) | 1999-02-26 | 1999-02-26 | Kristallmodifikation C von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino/incarbonsäure |
DE19908449.1 | 1999-02-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1342160A true CN1342160A (zh) | 2002-03-27 |
CN1191253C CN1191253C (zh) | 2005-03-02 |
Family
ID=7899027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB008043558A Expired - Fee Related CN1191253C (zh) | 1999-02-26 | 2000-02-14 | 8-氰基-1-环丙基-7-(1s,6s-2,8-二氮杂双环[4.3.0]壬-8-基)-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸的结晶变体c |
Country Status (26)
Country | Link |
---|---|
US (1) | US6649762B1 (zh) |
EP (1) | EP1155018B1 (zh) |
JP (1) | JP2002538158A (zh) |
KR (1) | KR100756471B1 (zh) |
CN (1) | CN1191253C (zh) |
AT (1) | ATE226952T1 (zh) |
AU (1) | AU763003B2 (zh) |
BR (1) | BR0008493A (zh) |
CA (1) | CA2362801A1 (zh) |
CZ (1) | CZ299700B6 (zh) |
DE (2) | DE19908449A1 (zh) |
DK (1) | DK1155018T3 (zh) |
ES (1) | ES2181644T3 (zh) |
HK (1) | HK1044948B (zh) |
HU (1) | HUP0200006A3 (zh) |
IL (2) | IL144702A0 (zh) |
NO (1) | NO320191B1 (zh) |
NZ (1) | NZ513750A (zh) |
PL (1) | PL349368A1 (zh) |
PT (1) | PT1155018E (zh) |
RU (1) | RU2248356C2 (zh) |
SK (1) | SK285562B6 (zh) |
TR (1) | TR200102434T2 (zh) |
UA (1) | UA70356C2 (zh) |
WO (1) | WO2000052009A1 (zh) |
ZA (1) | ZA200106289B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19854355A1 (de) | 1998-11-25 | 2000-05-31 | Bayer Ag | Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
DE19854356A1 (de) | 1998-11-25 | 2000-05-31 | Bayer Ag | Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
DE19908449A1 (de) * | 1999-02-26 | 2000-08-31 | Bayer Ag | Kristallmodifikation C von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino/incarbonsäure |
DE19908448A1 (de) | 1999-02-26 | 2000-08-31 | Bayer Ag | Kristallmodifikation D von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo[4.3.0)nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino incarbonsäure |
DE102004015981A1 (de) | 2004-04-01 | 2005-10-20 | Bayer Healthcare Ag | Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
DE102006049520A1 (de) * | 2006-10-20 | 2008-04-24 | Bayer Healthcare Ag | Verfahren zur Herstellung von Pradofloxacin |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2676521B2 (ja) | 1988-03-22 | 1997-11-17 | 北陸製薬株式会社 | キノロンカルボン酸化合物i型結晶の製造法 |
PL320190A1 (en) * | 1994-11-18 | 1997-09-15 | Upjohn Co | Novel, physically stable form of fuoroquinolone |
DE19546249A1 (de) * | 1995-12-12 | 1997-06-19 | Bayer Ag | Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen |
DE19633805A1 (de) * | 1996-02-23 | 1997-08-28 | Bayer Ag | Gegenenenfalls substituierte 8-Cyan-l-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäuren und ihre Derivate |
ES2184060T3 (es) * | 1996-02-23 | 2003-04-01 | Bayer Ag | Acidos 8-cian-1-ciclopropil-7-(2,8-diazabiciclo(4,3,0)-noman -8-il)-6-fluor-1,4-dihidro-4-oxo-3-quinolincarboxilicos, en caso dado substituidos, y sus derivados. |
DE19854355A1 (de) | 1998-11-25 | 2000-05-31 | Bayer Ag | Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
DE19854356A1 (de) | 1998-11-25 | 2000-05-31 | Bayer Ag | Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
DE19908449A1 (de) * | 1999-02-26 | 2000-08-31 | Bayer Ag | Kristallmodifikation C von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino/incarbonsäure |
DE19908448A1 (de) | 1999-02-26 | 2000-08-31 | Bayer Ag | Kristallmodifikation D von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo[4.3.0)nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino incarbonsäure |
-
1999
- 1999-02-26 DE DE19908449A patent/DE19908449A1/de not_active Withdrawn
-
2000
- 2000-02-14 TR TR2001/02434T patent/TR200102434T2/xx unknown
- 2000-02-14 PT PT00909166T patent/PT1155018E/pt unknown
- 2000-02-14 JP JP2000602235A patent/JP2002538158A/ja not_active Withdrawn
- 2000-02-14 BR BR0008493-0A patent/BR0008493A/pt not_active Application Discontinuation
- 2000-02-14 DK DK00909166T patent/DK1155018T3/da active
- 2000-02-14 RU RU2001126300/04A patent/RU2248356C2/ru not_active IP Right Cessation
- 2000-02-14 ES ES00909166T patent/ES2181644T3/es not_active Expired - Lifetime
- 2000-02-14 UA UA2001096578A patent/UA70356C2/uk unknown
- 2000-02-14 WO PCT/EP2000/001202 patent/WO2000052009A1/de active IP Right Grant
- 2000-02-14 US US09/914,090 patent/US6649762B1/en not_active Expired - Fee Related
- 2000-02-14 AU AU31543/00A patent/AU763003B2/en not_active Ceased
- 2000-02-14 HU HU0200006A patent/HUP0200006A3/hu unknown
- 2000-02-14 EP EP00909166A patent/EP1155018B1/de not_active Expired - Lifetime
- 2000-02-14 CA CA002362801A patent/CA2362801A1/en not_active Abandoned
- 2000-02-14 DE DE50000700T patent/DE50000700D1/de not_active Expired - Fee Related
- 2000-02-14 KR KR1020017009811A patent/KR100756471B1/ko not_active IP Right Cessation
- 2000-02-14 IL IL14470200A patent/IL144702A0/xx active IP Right Grant
- 2000-02-14 CZ CZ20013064A patent/CZ299700B6/cs not_active IP Right Cessation
- 2000-02-14 AT AT00909166T patent/ATE226952T1/de not_active IP Right Cessation
- 2000-02-14 NZ NZ513750A patent/NZ513750A/en unknown
- 2000-02-14 CN CNB008043558A patent/CN1191253C/zh not_active Expired - Fee Related
- 2000-02-14 PL PL00349368A patent/PL349368A1/xx not_active Application Discontinuation
- 2000-02-14 SK SK1195-2001A patent/SK285562B6/sk unknown
-
2001
- 2001-07-31 ZA ZA200106289A patent/ZA200106289B/en unknown
- 2001-08-02 IL IL144702A patent/IL144702A/en not_active IP Right Cessation
- 2001-08-21 NO NO20014061A patent/NO320191B1/no unknown
-
2002
- 2002-09-04 HK HK02106521.3A patent/HK1044948B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1191253C (zh) | 8-氰基-1-环丙基-7-(1s,6s-2,8-二氮杂双环[4.3.0]壬-8-基)-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸的结晶变体c | |
CN1217944C (zh) | 8-氰基-1-环丙基-7-(1s,6s-2,8-二氮杂双环(4.3.0)壬-8-基)-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸的结晶变体d | |
RU2248355C2 (ru) | 8-циан-1-циклопропил-7-(1s,6s-2,8-диазабицикло[4,3,0]нонан-8-ил)-6- фтор-1, 4-дигидро-4-оксо-3-хинолинкарбоновая кислота кристаллической модификации в и лекарственное средство на ее основе, обладающее действием против патогенных бактерий | |
RU2247122C2 (ru) | 8-циан-1-циклопропил-7-(1s,6s-2,8- диазабицикло[4,3,0]нонан-8-ил)-6-фтор-1, 4-дигидро-4-оксо-3-хинолинкарбоновая кислота кристаллической модификации а и лекарственное средство, обладающее действием против патогенных бактерий | |
MXPA01008651A (en) | Crystal modification c of 8-cyano-1-cyclopropyl-7- (1s, 6s-2,8- diazabicyclo -[4.3.0]nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic | |
MXPA01008650A (en) | Crystal modification d of 8-cyano-1-cyclopropyl-7- (1s, 6s- 2,8- diazabicyclo- [4.3.0]nonan-8-yl) -6-fluoro -1,4-dihydro -4-oxo -3-quinoline carboxylic acid | |
MXPA01005230A (en) | Crystal modification a of 8-cyano-1- cyclopropyl -7-(1s,6s-2, 8-diazabicyclo [4.3.0]nonan -8-yl)-6- fluoro-1, 4-dihydro- 4-oxo-3- quinoline carboxylic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050302 |